

## INFUSION SPECIALISTS' IV IRON SUBSTITUTION PROTOCOL

Agents listed in the tables below have been deemed to have similar therapeutic benefit with similar advserse reaction profiles. As such, the following substitutions may occur at the onset of the patient's treatment.

\*\*If payer guidelines mandate the use of Venofer due to step therapy or tiered treatment options, eligible orders may be automatically substituted to Venofer.

Eligible to be switched:	Will switch to:
Injectafer (ferric carboxymaltose) 750 mg IV x2 doses, separated by at least 7 days Feraheme (ferumoxytol) 510 mg IV x2 doses, separated by 3-8 days INFeD (iron dextran) 1000 mg IV x1 dose	<b>Venofer</b> (iron sucrose) 200 mg IV x5 doses, each dose separated by 2 to 7 days
	*Alternate dosing regimen if needed* Venofer (iron sucrose) 300 mg IV x3 doses, each dose separated by 3 to 7 days

\*\*In the absence of payer, physician, or patient preference, eligible orders may be substituted for Injectafer.

Eligible to be switched:	Will switch to:
Venofer (iron sucrose) 200 mg IV x5 doses, each dose separated by 2 to 7 days Venofer (iron sucrose) 300 mg IV x3 doses, each dose separated by 3 to 7 days Feraheme (ferumoxytol) 510 mg IV x2 doses, separated by 3-8 days INFeD (iron dextran) 1000 mg IV x1 dose	<b>Injectafer</b> (ferric carboxymaltose) 750 mg IV x2 doses, separated by at least 7 days